A retrospective analysis of the efficacy and safety of dicycloplatin in the treatment of malignant tumor
10.3969/j.issn.1006-0111.201904096
- VernacularTitle:双环铂治疗恶性肿瘤疗效和安全性回顾性分析
- Author:
Shuang ZHANG
1
;
Mengli CHEN
1
;
Hong YIN
1
;
Fenghua XU
1
Author Information
1. Department of Pharmacy, PLA General Hospital, Beijing 100853, China.
- Keywords:
discycloplatin;
malignant tumor;
clinical therapy;
effectiveness evaluation;
side effects
- From:
Journal of Pharmaceutical Practice
2020;38(2):179-183
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the short-term efficacy and adverse reactions of dicycloplatin in the treatment of malignant tumors. Methods A retrospective analysis was performed in our hospital from January 2017 to August 2018 using dicycloplatin to treat patients with malignant tumors. The efficacy and adverse reactions were evaluated after at least 2 cycles of chemotherapy. Results Among the 20 patients with an average of 4 cycles of chemotherapy, 1 had complete remission (CR), 4 had partial remission (PR), 7 had stable diseases (SD), 8 had progression (PD). The total efficacy was 25%. The control rate was 60%. The KPS scores for quality of life was higher than that before treatment (P<0.05). The main adverse effects during chemotherapy were bone marrow suppression, gastro-intestinal reactions. The incidence of leukopenia, thrombocytopenia, reduced hemoglobin, nausea vomiting and liver damage was 45%, 35%, 50%, 20%, and 5%, respectively. Conclusion Dicycloplatin-based chemotherapy has a good curative effect on malignant tumors, and the adverse reactions are mild and tolerable, which deserves further clinical observation and application.
